{"id":58714,"date":"2026-03-04T12:50:37","date_gmt":"2026-03-04T04:50:37","guid":{"rendered":"https:\/\/flcube.com\/?p=58714"},"modified":"2026-03-04T12:50:38","modified_gmt":"2026-03-04T04:50:38","slug":"sino-biopharma-licenses-rovadicitinib-to-sanofi-in-1-53b-deal-first-in-class-jak-rock-inhibitor-goes-global","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58714","title":{"rendered":"Sino Biopharma Licenses Rovadicitinib to Sanofi in $1.53B Deal \u2013 First\u2011in\u2011Class JAK\/ROCK Inhibitor Goes Global"},"content":{"rendered":"\n

Sino Biopharmaceutical Ltd (HKG:\u202f1177<\/a>)<\/strong> announced a licensing agreement<\/strong> with Sanofi SA (NASDAQ:\u202fSNY<\/a>)<\/strong> for rovadicitinib<\/strong>, a first\u2011in\u2011class JAK\/ROCK dual inhibitor<\/strong>. Under the agreement, Chia Tai\u2011Tianqing<\/strong>, Sino Bio’s subsidiary, grants Sanofi exclusive global rights<\/strong> to develop, manufacture, and commercialize<\/strong> the asset. Sino Bio is eligible for up to USD\u202f1.53\u202fbillion<\/strong>\u2014including USD\u202f135\u202fmillion upfront<\/strong> and tiered double\u2011digit royalties<\/strong>\u2014marking one of the largest Chinese biotech out\u2011licensing deals<\/strong> to date.<\/p>\n\n\n\n

Transaction Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licensor<\/strong><\/td>Sino Biopharmaceutical Ltd (HKG:\u202f1177) via Chia Tai\u2011Tianqing<\/td><\/tr>
Licensee<\/strong><\/td>Sanofi SA (NASDAQ:\u202fSNY)<\/td><\/tr>
Licensed Asset<\/strong><\/td>Rovadicitinib<\/td><\/tr>
Rights Granted<\/strong><\/td>Exclusive worldwide development, manufacturing, commercialization<\/td><\/tr>
Upfront Payment<\/strong><\/td>USD\u202f135\u202fmillion<\/strong><\/td><\/tr>
Milestone Potential<\/strong><\/td>Up to USD\u202f1.53\u202fbillion<\/strong> (development, regulatory, sales)<\/td><\/tr>
Royalties<\/strong><\/td>Tiered, up to double digits<\/strong> on annual net sales<\/td><\/tr>
Closing Conditions<\/strong><\/td>Subject to regulatory approvals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Drug Profile \u2013 Rovadicitinib<\/h2>\n\n\n\n
Feature<\/th>Detail<\/th><\/tr><\/thead>
Class<\/strong><\/td>First\u2011in\u2011class, potent oral small molecule<\/td><\/tr>
Targets<\/strong><\/td>JAK\/ROCK dual inhibition<\/strong><\/td><\/tr>
Mechanism<\/strong><\/td>Anti\u2011inflammatory + anti\u2011fibrotic effects via synergistic dual pathway blockade<\/td><\/tr>
China Approval<\/strong><\/td>March\u202f2026<\/strong>: First\u2011line intermediate\u20112\/high\u2011risk myelofibrosis (PMF, PPV\u2011MF, PET\u2011MF)<\/td><\/tr>
Pipeline Expansion<\/strong><\/td>Chronic graft\u2011versus\u2011host disease (cGVHD) and other indications<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Implications<\/h2>\n\n\n\n